- The ideal complement to DSG’s real-time, X-ray-free guidance technology
- Seeking industrial partnerships
PARIS, August 24, 2026 – 6:00 p.m. CEST – SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its digital surgical guidance (DSG®) technology—which measures the electrical conductivity of tissues locally in real time—to ensure the safe and simplified placement of bone implants, announced today that it has been granted a new U.S. patent by the USPTO (U.S. Patent and Trademark Office) for a robotically assisted ultrasound technology designed to determine the entry point and pedicle drilling trajectory from the bony surface of the spine.
Stéphane Bette, Deputy CEO and Co-founder of SpineGuard, stated: « Following our presentation at the CFA conference in April and the defense of the science thesis last December, we are very pleased with the granting of this patent in our largest market. The technology invented by SpineGuard’s scientific team uses ultrasound in an innovative way to determine—without using X-rays—the entry point and drilling direction from the posterior surface of the bone. In a context where surgical assistance systems often present the drawback of relying heavily on X-rays, this technology offers significant value. When combined with our DSG technology for real-time bone breach detection, it serves as the ideal complement before the drill bit penetrates the bone to perform the drilling. This new patent demonstrates our continued commitment to innovation, and the next step is to seek an industrial partner to commercialize it.»
Since its founding, SpineGuard has developed and maintained a significant intellectual property portfolio that currently includes 11 patent families and 3 registered trademarks in key regions such as Europe, the United States, China, and Japan.
About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices embedding its technology. Over 110,000 surgical procedures have been secured worldwide thanks to DSG® and 39 studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard is expanding the scope of its DSG® technology to the treatment of scoliosis via anterior approach, sacroiliac joint fusion, dental implantology and innovations such as the « smart » pedicle screw and power drill or surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives. For further information, visit www.spineguard.com
Disclaimer
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
Contacts
SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com
Anne-Charlotte Millard
CFO
Tél. : +33 1 45 18 45 19
ac.millard@spineguard.com
NewCap
Investor Relations & Financial Communication
Mathilde Bohin
Tel: +33 1 44 71 94 94
spineguard@newcap.eu